Validation of ALFA 1200 score in patients with AML >60 years treated with double nucleoside-based low-intensity therapy.

ABSTRACT:

SUBMITTER: Venugopal S 

PROVIDER: S-EPMC9647734 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature